Hyaluronic acid nanocapsules for the intracellular delivery of anticancer drugs

Abstract

The main goal of this thesis has been the development of hyaluronic acid nanocapsules (HA-NCs) as a multifunctional platform for the encapsulation and delivery of diverse anticancer drugs, such as hydrophobic drugs and hydrophilic biomolecules. The first step was the development of a spontaneous emulsification method, where HA-NCs were formulated without the need of organic solvents, heat or high energy input, providing conditions for the incorporation of sensible biomolecules while decreasing the environmental impact. Another advantage of this system is based on the use of a hydrophobically modified HA derivative that allowed the preparation of HA-NCs by hydrophobic interactions rather than by electrostatic forces, and thus, it reduced the toxicity associated to the addition of a cationic surfactant as counterion. Once formulated, HA-NCs had a size around 130 nm and a negative zeta potential about -20 mV. Moreover, these NCs were markedly stable under storage conditions and diluted in human plasma, taking forward this system as a potential carrier for intravenous administration. The versatility of this nanocarrier was confirmed by the incorporation of different drug models: docetaxel, a cytostatic drug, was incorporated into the oil core, whereas anti-gasdermin B, a monoclonal antibody, was entrapped into the polymeric shell. Docetaxel was highly encapsulated, released in a sustained manner and its cytotoxicity in A549 lung cancer cell line was maintained. Finally, anti-gasdermin B was successfully associated to the polymeric shell of HA-NCs and its intracellular delivery confirmed by confocal microscopy. Once inside the cell, anti-gasdermin B was able to escape the endosomal compartment and to target the intracellular protein gasdermin B, promoting an important decrease in the migratory and invasive behavior of HCC1954 breast cancer cell line. All these results highlight the potential of self-emulsifying HA-NCs as multifunctional systems to carry diverse anticancer drugs, with special emphasis in the intracellular delivery of monoclonal antibodies, an ambitious challenge that could open new avenues to fight cancer.